title: Superparamagnetic iron oxide nanoparticles for delivery of tissue plasminogen activator.
abstract: Magnetic nanoparticle (MNP) modified by carboxymethyl dextran (CMD) was synthesized and characterized by Fourier transform infrared spectroscopy, transmission electron microscopy, superconducting quantum interference device, dynamic light-scattering, thermogravimetric analysis, and X-ray diffraction. CMD coating on the particle surface provides abundant -COOH functional groups for conjugating with a thrombolytic drug, recombinant tissue plasminogen activator (rtPA). CMD-coated MNP (CMD-MNP) prepared with higher CMD/MNP ratios had higher CMD content, less iron content, more -COOH surface groups, smaller hydrodynamic diameter, and smaller saturation magnetization. The in vitro biocompatibility study using lactate dehydrogenase assays indicated that CMD-MNP elicited no cell cytotoxicity. The optimum drug loading could be achieved by contacting 0.25 mg rtPA with 5 mg CMD-MNP where all rtPA is immobilized to the magnetic nanocarrier with full retention of its thrombolytic activity.
authors.affiliation: Department of Chemical and Materials Engineering, Chang Gung University Kwei-San, Taoyuan 333, Taiwan, ROC.
authors.forename: Jyh-Ping
authors.initials: JP
authors.lastname: Chen
authors.forename: Pei-Chin
authors.initials: PC
authors.lastname: Yang
authors.forename: Yunn-Hwa
authors.initials: YH
authors.lastname: Ma
authors.forename: Yu-Jen
authors.initials: YJ
authors.lastname: Lu
mesh_terms: D005290:Ferric Compounds / Q000737:chemistry*; D053768:Metal Nanoparticles; D046529:Microscopy, Electron, Transmission; D011994:Recombinant Proteins / Q000008:administration & dosage; D017550:Spectroscopy, Fourier Transform Infrared; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D014961:X-Ray Diffraction
chemical_list: D005290:Ferric Compounds; D011994:Recombinant Proteins; C000499:ferric oxide; D010959:Tissue Plasminogen Activator